Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 10/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229626 | 0.93 | PDCD1 (0.44) | PDCD1CD274HDAC1SCD | |
| SCHEMBL3232105 | 0.88 | PDCD1 (0.47) | PDCD1CD274HDAC1SCDMEN1 | |
| SCHEMBL3234640 | 0.84 | PDCD1 (0.64) | PDCD1CD274HDAC1 | |
| SCHEMBL3224966 | 0.82 | PDCD1 (0.56) | PDCD1CD274HDAC1SCD | |
| SCHEMBL3229254 | 0.82 | PDCD1 (0.51) | PDCD1CD274HDAC1SCDMEN1 | |
| SCHEMBL3221396 | 0.81 | CD274 (0.50) | PDCD1CD274HDAC1 | |
| SCHEMBL2384644 | 0.81 | HDAC1 (0.47) | PDCD1CD274HDAC1SCDMEN1 | |
| SCHEMBL3226070 | 0.80 | PDCD1 (0.48) | PDCD1CD274HDAC1SCDMEN1 | |
| SCHEMBL2383083 | 0.80 | PDCD1 (0.53) | PDCD1CD274HDAC1 | |
| SCHEMBL13569719 | 0.80 | PDCD1 (0.48) | PDCD1CD274HDAC1SCDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | PDCD1 4109/4885CD274 4707/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.